SMi Group presents Pharmaceutical Microbiology West Coast.

1. KEY BENEFITS FOR 2017:
• Discuss the challenges involved with microbial control with
Takeda
• Following the path to efficient sterility assurance with GSK
• Bimeda highlight the importance of environmental modelling
• Delve into the latest developments in rapid microbial
methods with Janssen
• Hear the latest on data integrity and compliance with Roche
SMi present the 7th in its series...
Hyatt Regency Mission Bay, San Diego, USA
Addressing the current challenges in sterility assurance, environmental monitoring
and RMM whilst evaluating the latest trends and opportunities for microbial control.
WORKSHOPS: 7TH
CONFERENCE:
8TH - 9TH
JUNE
2017
REGISTER BY 31ST MARCH AND SAVE $200
REGISTER BY 28TH APRIL AND SAVE $100
www.pharma-microbiology-usa.com
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
ACADEMIC & GROUP DISCOUNTS AVAILABLE @SMIPHARM
#smimicrobiology
PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS
Wednesday 7th June 2017, Hyatt Regency Mission Bay, San Diego, USA
Technologies for Monitoring Contamination Control
and Case Studies on Contamination Control
08.30 – 12.30
Workshop Leaders:
Jim Polarine Jr, Senior Technical Service Manager, STERIS Corporation
Andrew Bartko, Research Leader, Battelle Memorial Institute
Microbial Required Use for
Terminal Sterilization
13.30 – 17.30
Workshop Leader:
Jerry Dalfors, Principal, JD Technologies
Pharmaceutical
Microbiology West Coast
Sponsored by
CHAIRS FOR 2017:
• Donald Singer, GSK Fellow, Steriles Microbiology, R&D, GSK
• John Duguid, Senior Director, Research & Development,
Vericel Corporation
EXPERT SPEAKER PANEL INCLUDE:
• Ron Smith, Director, External Supply Integration Quality, Janssen
• Ren-Yo Forng, Scientific Director, Amgen
• Kevin Luongo, QC Sr. Scientist (Microbiology), Takeda
• Lina Orjuela, Microbiologist, Merck
• Paul Ricciatti, Sterility Assurance Manager, Bimeda
• Jeanne Moldenhauer, Vice President,
Excellent Pharma Consulting
• Akua Gilbert-Arthur, Principal Scientist,
Roche Molecular Systems

2. Pharmaceutical Microbiology West Coast
Day One | Thursday 8th June 2017 www.pharma-microbiology-usa.com
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
Donald Singer, GSK Fellow, Steriles Microbiology, R&D, GSK
OPENING ADDRESS
09.10 Retracing the path to sterility assurance: An USP journey
• Update on latest revisions of USP microbiology chapters
• Discussion of work activities for revising chapter on sterility
assurance
• Current thinking about sterile product evaluation topics
(bacterial endotoxins testing, alternative pyrogen test,
container closure integrity evaluation, sterility test)
Donald Singer, GSK Fellow, Steriles Microbiology, R&D, GSK
ENVIRONMENTAL MONITORING
09.50 The importance of environmental monitoring
• Environmental monitoring in today’s pharmaceutical
industry is imperative to avoid potential risks to consumers
and to save time and cost to manufacturers
• Rules governing dispersion of airborne microbial
contaminants and how contaminants can accumulate
in invisible vortices and airborne contamination
• How to evaluate representative sampling locations for
environmental monitoring during aseptic processes
Paul Ricciatti, Sterility Assurance Manager, Bimeda
10.30 Morning Coffee
11.00 Environmental monitoring trend analysis tools
• The importance of proper analysis and evaluation of
viable EM results.
• Development of a “tool box” in order to produce
specialized data reports.
• A case study in using the correct tools to demonstrate
environmental control in a cleanroom environment
Steve Walton, Technical Manager, Sterility Assurance, Sanofi
11.40 Gram negative LPS structural alterations in response to
environmental stimuli
• Overview of how gram negative bacteria adapt to
various environmental conditions
• The role of modulation of outer membrane components
has on facilitating environmental adaptation
• The effect of external stimuli and structural adaptation
has on the classical LPS architecture
John Dubczak, Director of Operations,
Charles River
12.20 Networking Lunch
CHALLENGES IN ENDOTOXIN RECOVERY & STERILITY ASSURANCE
13.20 Challenges in endotoxin testing
• Advantages of in-process control
• Issues occurring in the detection of endotoxins
• Utilising the alternative endotoxin reagents and/or
methods to detect potential contaminants in products
Ren-Yo Forng, Scientific Director, Amgen
14.00 Interactive extended training session:
Effects of cleanrooms and barrier systems
on environmental monitoring data
Recent warning letters show that manufacturers of aseptic
products are receiving the most 483s; many are related
to smoke studies. Smoke / Airflow Visualization tests are
often performed by third party certifiers. However, per
FDA guidance, dynamic in-situ air pattern analysis is
more complex. These studies should be investigative and
effective at identifying design flaws or airflow issues. They
should be performed using the correct type of smoke,
smoke density, and camera angles.
• A closer look at existing regulation
(e.g. Pharm. Eur., USP, PDA)
• Why do we need to implement rapid microbial
methods vs classical microbial methods?
• How to evaluate the best RMM for each application
• Validation strategy, regulatory strategy and examples
of return of experiences
Morgan Polen, Subject Matter Expert on Contamination
Control, Microrite
15.00 Afternoon Tea
15.30 Bringing the cleanroom online after an adverse event
• Environmental control of classified areas within a
biopharmaceutical facility - maintained by systems
controlling humidity, air temperature, air exchanges,
filtration and pressure differentials
• When any of these systems or practices fail, it’s
considered a “Worst Case Event” which has the potential
to impact the clean state of a Classified Area
• FDA Warning Letters and 483s will be covered that focus
on cleanroom shut down and start up procedures
Jeanne Moldenhauer, Vice President,
Excellent Pharma Consulting
16.10 Microbiological examination of non-sterile products
• Experience with USP <61> and USP <62> tests
• Utilising these test to provide harmonization with the
European Pharmacopeia methods
• Challenges incurred and lessons learnt
Elizabeth Hulanick, Microbiologist, Renaissance
Pharmaceuticals
16.50 Chairman’s Closing Remarks and Close of Day One
Sponsored by
Register online at www.pharma-microbiology-usa.com
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking
opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join
the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
bioMérieux Inc Like you, we are inquisitive microbiologists who rely on our experience to explore and innovate ways to keep your lab running
smoothly and ensure that your products are safe. Visit www.thepeoplebehindthescience.com to see what new science our people are
creating for you. Together, we are the people behind the science.
Charles River Protecting the integrity of your products requires a reliable partner at all critical junctures in the QC process. We’ve purposely
built our portfolio to bring you progressive products and services that deliver accurate, relevant and reliable data to fuel confident decisions
on product quality and contamination control. Our unique combination of Endosafe® endotoxin testing, Celsis® rapid microbial detection and
Accugenix® microbial identification and strain typing keeps your manufacturing operations running efficiently and smoothly, lowers your cost
to manufacture and protects your reputation. www.criver.com/products-services/manufacturing-support
Rapid Micro Biosystems delivers the Growth Direct™ System, an automated, non-destructive rapid detection and enumeration technology
based on the compendial method for microbial quality control in pharmaceutical manufacturing. The system automates and accelerates
detection and enumeration in the areas of environmental monitoring, bioburden and sterility testing eliminating manual steps and analysis. The
Company’s Growth DirectTM System detects contamination earlier, delivering compelling economic benefits to manufacturers, while improving
their quality process. The Growth Direct System is the first and only automated system that addresses all key microbial QC applications and fits
with current regulatory practices, a critical accelerator for adoption. Automated analysis eliminates error-prone manual steps and saves labor;
rapidly detecting contamination enables manufacturers to reduce inventory carrying costs, shorten manufacturing cycle time, and reduce
product losses, delivering significant cost savings and increased operational efficiency. www.rapidmicrobio.com

3. Pharmaceutical Microbiology West Coast
www.pharma-microbiology-usa.com Day Two | Friday 9th June 2017
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
John Duguid, Senior Director, Research & Development,
Vericel Corporation
RAPID MICROBIAL METHODS
OPENING ADDRESS
09.10 Challenges involved with microbial control
• A CMO-focused microbial control strategy
• The challenges with managing an external
manufacturing program
• Looking to the future
Kevin Luongo, QC Sr. Scientist (Microbiology), Takeda
09.50 Validation of a Rapid Microbial Method: Case studies for
microbial limits and sterility testing.
• Overview of the approach for testing equivalence of a
qualitative method
• Demonstrating equivalence to pour plate method for
Microbial Limits testing of betamethosone suspension
• Demonstrating equivalence to membrane filtration
sterility test method for a saline product
Ronald Smith, Director, External Supply Integration Quality,
Janssen
10.30 Morning Coffee
11.00 US approval of three rapid microbiological methods for
MACI product release
• Same day product release is needed for MACI®
(autologous cultured chondrocytes on porcine collagen
membrane)
• Automated rapid microbiological methods enable test
results within hours
• Regulatory requirements are continuing to evolve
John Duguid, Senior Director, Research & Development
Vericel Corporation
DATA INTEGRITY
11.40 Data integrity and compliance
• Current limitations with data integrity
• How to improve the reliability of data is necessary
to support clinical trials, product development and
manufacturing, and testing and reporting requirements
• Examining data integrity in relation to related to
pharmaceutical microbiology, including environmental
monitoring and laboratory analysis
Akua Gilbert-Arthur, Principal Scientist,
Roche Molecular Systems
12.20 Networking Lunch
13.20 Lessons learned in microbial data integrity management
• Data integrity within analytical and microbiology
laboratories for all phases of the drug product lifecycle
• What works well? How can it be improved?
• Examining the recently released draft guidance data
integrity and compliance with CGMP guidance for industry
Lina Orjuela, Microbiologist, Merck
14.00 Microbial data deviation investigations
• Common causes of MDD
• Microbial identification programs
• Collaborating with other departments
• When a MDD should be escalated to a DR
Jarett Scalzo, QC Microbiology Manager, Kite Pharma Inc.
BIOFILMS & OTHER CONTAMINANTS
14.40 Additional background on biofilm, its impacts in
healthcare, her discovery, and current testing.
• We are losing the war on bacteria. One of the reasons is
biofilm -- the sticky substance that bacteria form in order
to attach to surfaces and then shield the developing
colony from environmental stresses
• It is no coincidence that every bacterium on the lists
of the Center for Disease Control are biofilm-formers:
urgent threats (C. diff, etc.), pandemic threats
(pneumonia, T.B., E.coli, Salmonella, Listeria, cholera,
plague, etc.), bioterror threats (anthrax, etc.),, and
antimicrobial-resistant strains (MRSA, MDR-TB, CRES, etc.)
• As biofilm builds it captures other bacteria, and there is
evidence of horizontal gene transfer between different
species
• There are few remedies for biofilm. Scraping and
sterilization work, but they are short term. Biofilm was
recorded on a titanium plate within 30 seconds after
sterilization
• The human immune system, biocides and antibiotics are
designed to kill free-floating bacteria. Nothing known
can remove pre-formed biofilm at non-lethal doses
Cynthia Burzell, Founder & CSO, Aequor, Inc.
15.20 Afternoon Tea
15.50 Challenges with contamination issues
• Mold - A simple method to eliminate and prevent mold
anywhere.
• Biofilm - Simple and fast methods to eliminate and
prevent biofilm
• Spores - Simple ways to eliminate quickly and safe for
your equipment/surfaces
Brian Hubka, CEO, BGH International, LLC
16.30 Common errors in microbial identification and implications
• Phenotypic vs. Genotypic systems-capabilities and
deficiencies
• Deficient media quality control
• Microbiology laboratory training deficiencies that lead
to errors
• Growth media and incubation errors
• Gram staining errors
• What to do when in doubt
• Case studies
Ziva Abraham, CEO, Microrite
17.10 Chairman’s Closing Remarks and Close of Day Two
Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
MARKETING OPPORTUNITIES
Want to know how you can get involved? Interested in promoting your services to this market?
Contact Zoe Gale, SMi Marketing on +44 (0) 207 827 6132 or email: zgale@smi-online.co.uk
Supported byOfficial Media Partners:

4. Overview of the workshop:
This session will discuss pathways to use the data obtained from
environmental monitoring to provide proactive and practical
solutions for comprehending and managing everyday
pharmaceutical microbiology challenges. This presentation will
cover case studies on human flora and spore contamination
in cleanroom operations. The workshop will cover the most
common causes of contamination: operators, items brought
into the cleanroom, and degradation of the cleanroom over
time. Case studies in operator borne contamination will be
discussed as well as preventative long term solutions. Targeted
long term solutions will be discussed regarding the spore case
studies in a concerted effort to limit reoccurrences. The overall
objective and scope of this seminar will be to discuss specifi c
cases studies that have occurred in my years of experience
in the industry. The concepts of cleaning and disinfection,
application frequency, disinfectant rotation, and rinsing and
residue removal strategies will be covered as well.
Why should you attend this workshop:
This industry workshop will give attendees valuable insight into
the world of contamination control and troubleshooting fungal
and bacterial spore excursions in cleanrooms. Attendees will
gain new insight into common causes of CAPA investigations
which will cut down on time that is invested finding potential
causes for contamination which can cost an organization 50K
per investigation.
Programme
08.30 Registration & Coffee
09.00 Opening remarks & introductions
09.15 Introduction
• Conventional methods
• Limitations
09.45 Sensing fundamentals
• Absorption and fluorescence
• Vibrational and Raman spectroscopy
• Mass spectrometry
10.30 Morning Coffee
11.00 Utilisation of spectrometric methods
• Advantages and limitations of new methods
• Comparisons to traditional microbial quality control
11.30 Industry case studies
• Vegetative organisms
• Fungal spores
• Bacterial spores
12.15 Interactive exercise
12.30 End of workshop
About the Workshop Leaders:
Mr. Polarine is a senior technical service manager
at STERIS Corporation. He has been with STERIS
Corporation for sixteen years. His current technical
focus is microbial control in cleanrooms and other
critical environments. He is active as co-chair on the PDA’s
microbial investigations task force. He was a co-author on
PDA’s Technical Report #70 on Cleaning and Disinfection. He
is a member of the PDA’s Environmental Monitoring Group,
Contamination Control Group, and Biotech Interest Group.
Dr. Andrew P. Bartko received a B.S. from the
University of Pittsburgh in 1997 and a Ph.D. in physical
chemistry in 2002. Dr. Bartko is a senior scientist in
Battelle’s Technology Development Group where
he contributes to several applied spectroscopy efforts that
focus on biological and chemical sensing. Dr. Bartko is the
manager and technical leader of an interdisciplinary team
that is developing Battelle’s Resource Effective Bioidentifi
cation System (REBS).
About the Organisation:
STERIS is a global leader in infection
prevention, contamination control,
surgical and critical care technologies,
and more. STERIS is the world’s pre-eminent infection
prevention, decontamination, and surgical and critical care
company. Every day, the people of Battelle apply science
and technology to solving what matters most. At major
technology centers and national laboratories around the
world, Battelle conducts research and development, designs
and manufactures products, and delivers critical services for
government and commercial customers.
Technologies for Monitoring
Contamination Control and Case Studies
on Contamination Control
Workshop Leaders: Jim Polarine Jr, Senior Technical
Service Manager, STERIS Corporation and Andrew Bartko,
Research Leader, Battelle Memorial Institute
HALF-DAY PRE-CONFERENCE WORKSHOP
Wednesday 7th June 2017
08.30 – 12.30
Hyatt Regency, Mission Bay, San Diego, CA

5. Overview of the workshop:
Determining best way to work with Microorganisms to ensure
we have sterilization that verifies we have no patient risk or
product stability issues due to survival of the microorganism
or damage to the product due to sterilization.
Why should you attend this workshop:
Knowing how to most effectively establish your D-values,
Z-values, F-values and Fbio-values along with Fo, FH and
lethality based on your bioburdens and any biological
indicator you select to use in your process based on the
variables associated with so many different issues associated
with different products that all need to be proven to be
sterile prior to distribution.
Programme
13.30 Registration & Coffee
14.00 PNSU – BIOBURDEN – Probability Function D values,
Z values and Fo
• How were those established?
• Where Did “Fo” start relative the microbial
impact
• Microbiological D value variations
• Can’t typically use what the vendor provides for
D values and Z values based on your product
trying to be sterilized.
• Typical BI Death Curve and Fraction Negative
• D121 value, Z value and Determination of Fo
• Bioburden Monitoring and determination of
potential sterilization risk compared to any
biological indicator
15.30 Afternoon Tea
16.00 Recent FDA Sterilization Observations Resulting
in Warning Letters – Providing what the FDA has
written about a variety of different situations that
has caused significant concerns based on many
companies not having the correct perspective
about Microbiological Sterilization.
17.20 Closing remarks
17.30 End of workshop
About the Workshop Leader:
Mr. Jerry Dalfors has extensive (40+ years) of
business administration, consultative, technical
and managerial experience in the development
and manufacture of highly regulated
biopharmaceutical products including injectables,
biologics, medical devices and oral dosages. He has held
permanent employee, temporary employee and company
representative management positions with a multitude of
the major pharmaceutical and biotechnology companies in
the US. He has worked with or assisted more than two dozen
companies with the establishment of controlled document/
qualitysystems,FDAbriefingandsubmittaldocuments,project
management of several multimillion dollar projects including
design, start-up and validation to assure fast track FDA
approval by maintaining strict regulatory compliance during
all phases of engineering, construction, commissioning and
validation, and has written numerous submission documents
for product, process and facility approval/licensing which also
required the development of quality systems which included
customer complaint management, deviation management,
CAPA and associated site wide employee training. Each of
his projects have been received and accepted by the FDA
and other regulatory agencies. Jerry is considered and expert
in most all aspects of the biopharmaceutical and medical
device industry and has trained many FDA field inspectors on
a variety of topics. None of his work has ever received a 483
but has corrected and prevented many along with Warning
Letter remediation.
About the Organisation:
JD Technologies provides consulting, regulatory and
documentation support to the pharmaceutical and
biopharmaceutical industries. JD Technologies prides itself
on being able to succesfully carry a project from concept to
completion, and integrating with other company employees
and contractors in a team effort.
Microbial Required Use for
Terminal Sterilization
Workshop Leader:
Jerry Dalfors, Principal, JD Technologies
HALF-DAY PRE-CONFERENCE WORKSHOP
Wednesday 7th June 2017
13.30 – 17.30
Hyatt Regency, Mission Bay, San Diego, CA

6. Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the
event. Regretfully cancellation after this time cannot be accepted. We will however provide the
conferencesdocumentationviatheDocumentPortaltoanydelegatewhohaspaidbutisunable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able
to provide documentation in these circumstances. We cannot accept cancellations of orders
placed for Documentation or the Document Portal as these are reproduced specifically to order.
If we have to cancel the event for any reason, then we will make a full refund immediately, but
disclaim any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about
other products and services. Unless you tick here □ we may also share your data with third parties
offeringcomplementaryproductsorservices.Ifyouhaveanyqueriesorwanttoupdateanyofthe
data that we hold then please contact our Database Manager databasemanager@smi-online.
co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your
address on the attached letter.
Payment must be made to SMi Group Ltd, and received before the event, by one of the
following methods quoting reference P-217 and the delegate’s name. Bookings made within
7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 11775391
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB75 LOYD 3000 0911 7753 91
□ Cheque We can only accept US Dollar Cheques.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
VAT at 20% is charged on document portal and literature distribution for all UK customers
and for those EU Customers not supplying a registration number for their own country here.
______________________________________________________________________________________
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
EARLY BIRD
DISCOUNT
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712
I cannot attend but would like to purchase access to the following
Document Portal/paper copy documentation Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
Unique Reference Number
Our Reference LVP-217
DELEGATE DETAILS
Terms and Conditions of Booking
PAYMENT
VAT
CONFERENCE PRICES
DOCUMENTATION
VENUE Hyatt Regency, Mission Bay, San Diego, CA, USA
PHARMACEUTICAL MICROBIOLOGY WEST COAST
Conference: Thursday 8th & Friday 9th June 2017, Hyatt Regency, Mission Bay, San Diego, CA, USA Workshop: Wednesday 7th June 2017, San Diego, CA, USA
4 WAYS TO REGISTER
www.pharma-microbiology-usa.com
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd,
Ground & First Floor, 1 Westminster Bridge Road London, SE1 7XW, UK
□ Book by 31st March to receive $200 off the conference price
□ Book by 28th April to receive $100 off the conference price
I would like to attend: (Please tick as appropriate) Fee
□ Conference & 2 Workshops $2897.00
□ Conference & 1 Workshop A □ B □ $2398.00
□ Conference only $1899.00
□ 2 Workshops $998.00
□ 1 Workshop only A □ B □ $499.00
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees $1598 + VAT $1917.60
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.